NasdaqGS - Nasdaq Real Time Price USD

DexCom, Inc. (DXCM)

Compare

69.34

-0.28

(-0.40%)

At close: August 30 at 4:00 PM EDT

69.31

-0.03

(-0.04%)

After hours: August 30 at 7:55 PM EDT

Is DexCom a Millionaire-Maker Stock?

The stock has delivered superior returns in the past 19 years.

Motley Fool 18 hours ago

DXCM
-0.40%
VRTX
+0.51%
AAPL
DexCom Stock Got Crushed After an Earnings Miss. A New Product Could Bail It Out.

Management miscues derailed the company’s growth prospects. But a new glucose monitor for Type 2 diabetes and some changes in how the company sells could lead to a rebound.

Barrons.com 3 days ago

DXCM
-0.40%
Dexcom Announces Upcoming Conference Presentation

SAN DIEGO, August 28, 2024--DexCom, Inc. (NASDAQ:DXCM) today announced that Kevin Sayer, Chairman, President and Chief Executive Officer, and Jereme Sylvain, Executive Vice President and Chief Financial Officer, will present an update on the company at the 2024 Wells Fargo Healthcare Conference on Wednesday, September 4th.

Business Wire 5 days ago

DXCM
-0.40%
DexCom Stock May Gain on Expanded Reach After Stelo's US Launch

DXCM announces that its OTC CGM, Stelo, is now available for purchase in the United States without a prescription.

Zacks 6 days ago

DXCM
-0.40%
ABM
Will New 'Milestone' Glucose Monitor Help Dexcom Stock Bounce Back?

Dexcom launched its new continuous glucose monitor on Monday. But the move didn't help troubled Dexcom stock.

Investor's Business Daily 7 days ago

DXCM
-0.40%
Jim Cramer Says ‘One of the Most Dramatic Declines Of This Year Comes From DexCom Inc. (DXCM)’

We recently compiled a list of the Jim Cramer Wants You to Check These 10 Stocks. In this article, we are going to take a look at where DexCom Inc. (NASDAQ:DXCM) stands against the Jim Cramer-approved stocks. Jim Cramer noticed a strange pattern during the recent winning streak last week. According to Cramer, when a company […]

Insider Monkey 7 days ago

DXCM
-0.40%
Dexcom prices first over-the-counter glucose monitor

Known as Stelo, the device is intended for people who don’t take insulin and costs $89 per month.

MedTech Dive 7 days ago

DXCM
-0.40%
Stelo by Dexcom, the First Over-the-Counter Glucose Biosensor in the U.S., Is Now Available

SAN DIEGO, August 26, 2024--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that Stelo, the first over-the-counter glucose biosensor in the U.S., is now available for purchase without a prescription4 at Stelo.com.

Business Wire 7 days ago

DXCM
-0.40%
Viking Therapeutics could be a new winner in the GLP-1 space

GLP-1 weight-loss drugs have taken the pharmaceutical world by storm, Novo Nordisk (NVO) and Eli Lilly (LLY) making a name for the class of drugs through their own landmark brands. But what about the other pharma players pushing into the weight-loss space? Julie Hyman is joined by RSE Ventures Co-Founder and CEO Matt Higgins for the latest installment of Good Buy or Goodbye to talk about why he is bullish on Viking Therapeutics (VKTX) in its GLP-1 innovations, and why he is bearish on glucose monitoring device manufacturer DexCom (DXCM) as more consumers adopt weight-loss drugs to lower the riskssof diabetes. "We all know what Eli Lilly, and what Novartis has done. But it's a massive TAM [total addressable market], it's a $150 billion market. And this is a biotechnology firm, probably like 30 people, and they are onto something pretty amazing," Higgins says about Viking. "They are working on two products: one is a shot that you would take once a month, and the other is a pill, which is the holy grail and early studies show that it's being very well tolerated." Higgins cites the growing use cases for GLP-1s, particularly in the treatment of pre-diabetic patients, as a forceful headwind to DexCom. Its glucose monitoring devices are only designed for a single sort of use and does not allow DexCom to pivot very far from its central business. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Luke Carberry Mogan.

Yahoo Finance Video 12 days ago

VKTX

DXCM
-0.40%
Is It Time to Buy July's Worst-Performing S&P 500 Stocks?

These stocks took a dive recently, and that could spell opportunity.

Motley Fool 12 days ago

^GSPC

DXCM
-0.40%
CRWD
These Two Stocks Plunged After Eli Lilly Drug Study Showed Diabetes Promise

Shares of two companies that provide devices for patients with diabetes fell sharply after a study showed Eli Lilly's popular drug cut diabetes risks.

Investopedia 13 days ago

LLY

DXCM
-0.40%
PODD
-1.16%
Should You Hold DexCom (DXCM)?

Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Mid Cap Growth Fund” second quarter 2024 investor letter. A copy of the letter can be downloaded here. Having carried over some of the strength from the previous year into the first quarter, mid-cap stocks reversed course and ended the second quarter at a […]

Insider Monkey 13 days ago

DXCM
-0.40%
3 US Stocks Trading At Estimated Discounts Up To 45.2%

The U.S. stock market has been on an impressive winning streak, with the S&P 500 and Nasdaq Composite extending their gains as investor sentiment improves and economic concerns ease. As major indices approach record highs, it presents a compelling opportunity to explore stocks that may still be trading at significant discounts. In this favorable market environment, identifying undervalued stocks can offer potential for substantial returns, particularly when these companies are poised to...

Simply Wall St. 13 days ago

DXCM
-0.40%
HWM

VRT
2 Unstoppable Healthcare Stocks to Buy Right Now With Less Than $200

These companies' growth paths should only be briefly interrupted by headwinds.

Motley Fool 15 days ago

DXCM
-0.40%
NVS
2 Growth Stocks to Buy at a Discount

Look beyond share price at the business behind the stock, and you might find there's more for investors to consider.

Motley Fool 15 days ago

DXCM
-0.40%
OPEN
What Makes DexCom, Inc. (DXCM) a Good Diabetes Stock to Buy According to Hedge Funds?

We recently compiled a list of the 7 Best Diabetes Stocks To Buy Now. In this article, we are going to take a look at where DexCom, Inc. (NASDAQ:DXCM) stands against the other diabetes stocks. According to the WHO, approximately 422 million individuals globally suffer from diabetes, with the majority residing in countries with low or […]

Insider Monkey 17 days ago

DXCM
-0.40%
S&P 500 Gains and Losses Today: Amcor Slides After Packaging Firm's Sales Miss

The S&P 500 added 0.2% on Friday, Aug. 16, closing out a strong week and completing its recovery from a selloff at the beginning of the month.

Investopedia 17 days ago

AMCR

^GSPC

TPR
DexCom's (DXCM) G7 CGM Coverage Expanded for Quebec Residents

DexCom (DXCM) announces that Quebec residents aged two years and older living with type 1 diabetes may now be eligible to receive coverage for Dexcom G7.

Zacks 17 days ago

DXCM
-0.40%
DGX

ABM
1 Growth Stock Down 43% to Buy Right Now

Here's why DexCom should be on your radar after the company's share price plunged recently.

Motley Fool 17 days ago

DXCM
-0.40%
Medtronic (MDT) Progresses in CGM With New Approval, Alliance

The FDA approval for Medtronic's (MDT) Simplera CGM sets the stage for further regulatory submissions of the updated InPen smart insulin pen app.

Zacks 18 days ago

MDT

DXCM
-0.40%
ABT

Performance Overview

Return	DXCM	S&P 500
YTD	-44.12%	+18.42%
1-Year	-31.06%	+25.59%
3-Year	-46.73%	+25.26%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

DexCom, Inc. (DXCM)

Is DexCom a Millionaire-Maker Stock?

DexCom Stock Got Crushed After an Earnings Miss. A New Product Could Bail It Out.

Dexcom Announces Upcoming Conference Presentation

DexCom Stock May Gain on Expanded Reach After Stelo's US Launch

Will New 'Milestone' Glucose Monitor Help Dexcom Stock Bounce Back?

Jim Cramer Says ‘One of the Most Dramatic Declines Of This Year Comes From DexCom Inc. (DXCM)’

Dexcom prices first over-the-counter glucose monitor

Stelo by Dexcom, the First Over-the-Counter Glucose Biosensor in the U.S., Is Now Available

Viking Therapeutics could be a new winner in the GLP-1 space

Is It Time to Buy July's Worst-Performing S&P 500 Stocks?

These Two Stocks Plunged After Eli Lilly Drug Study Showed Diabetes Promise

Should You Hold DexCom (DXCM)?

3 US Stocks Trading At Estimated Discounts Up To 45.2%

2 Unstoppable Healthcare Stocks to Buy Right Now With Less Than $200

2 Growth Stocks to Buy at a Discount

What Makes DexCom, Inc. (DXCM) a Good Diabetes Stock to Buy According to Hedge Funds?

S&P 500 Gains and Losses Today: Amcor Slides After Packaging Firm's Sales Miss

DexCom's (DXCM) G7 CGM Coverage Expanded for Quebec Residents

1 Growth Stock Down 43% to Buy Right Now

Medtronic (MDT) Progresses in CGM With New Approval, Alliance

Performance Overview